MUMBAI: Suven Life Sciences Ltd will invest $25 million in human clinical trials to test the efficacy and safety of its drug candidate for Alzheimer’s disease, a top company executive said.
The company completed the first phase of the trial of its drug candidate SUVN-502 in April 2009 and was trying to license out further development to other companies. Suven was asked by some interested firms to provide proof of concept, which the proposed human clinical trials seek to establish, before they stepped in, according to chairman and chief executive Venkat Jasti…